This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 3 of 592

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

By Adam Feuerstein

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.

11:35AM 04/15/15

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts

By Adam Feuerstein

The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.

09:46AM 04/14/15

Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO

By Adam Feuerstein

Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.

08:43AM 04/14/15

Athersys Future Hinges on Stem Cell Stroke Study Results

By Adam Feuerstein

The verdict on an experimental stem cell therapy developed by Athersys to assist the recovery of stroke patients is coming on April 19.

09:32AM 04/13/15

Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:01AM 04/10/15

Cytori CEO Tries His Best to Spin Stem-Cell Company's Setbacks

By Adam Feuerstein

As the CEO of a struggling stem-cell therapy company, Hedrick needs to don brightly colored pom-poms just to grab investors' attention.

02:51PM 04/08/15

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

By Adam Feuerstein

Investors were treated to a hepatitis C data dump Wednesday morning ahead of a European liver disease meeting later in the month.

10:08AM 04/08/15

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

By Adam Feuerstein

The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.

08:02AM 04/07/15

Ocular Therapeutix Eye-Pain Plug Flops Confirmatory Pivotal Trial

By Adam Feuerstein

Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.

05:22PM 04/06/15

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

05:57AM 04/02/15

Page 3 of 592

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs